CROSSPOINT Therapeutics

Private

South KoreaHealthcare & Life Scienceshttps://www.crosspointrx.com/

Last Round

VC Round

Mar 4, 2026

Total Funding Raised

$2.82M

Company Overview

CROSSPOINT Therapeutics is a biotechnology company that develops next-generation antibody therapies using its proprietary Stealth-Body platform to reduce toxicity and side effects.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

antibody engineeringantibody-drug conjugatesADCimmunotherapyFc-silencingnext-gen biologicsoncology therapeuticsbiotech platformdrug delivery platformtherapeutic indexpreclinical drug developmentbiotech licensingprotein deliverygene deliverydrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CROSSPOINT Therapeutics Comparables

Compare CROSSPOINT Therapeutics with similar companies based on industry and business-model similarity.

CROSSPOINT Therapeutics comparables — related companies by embedding similarity
Company	Similarity	Market Cap
mAbsolve Ltd.	91%
Proteinea	78%
Xencor, Inc.	69%

View all Comparables

CROSSPOINT Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
VC Round	Mar 4, 2026
Grant	Aug 8, 2024
Seed	Apr 1, 2024

View all Funding Rounds

Key People

Founding team and executive leadership

Ki Hwan C.

Chief Technology Officer

Executive Team

CROSSPOINT Therapeutics Investors

Notable investors and investment history

CROSSPOINT Therapeutics investors
Investor	Rounds
Kite Entrepreneurship Foundation	Seed
Korea University Holdings	Seed
Infobank Corp	Seed
Bigbang Angels, Inc.	Seed
Korea Omega Investment Corp	Seed
Kudos Ventures	VC Round
Government of South Korea	Grant

View all Investors

CROSSPOINT Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

CROSSPOINT Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CROSSPOINT Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth Korea

Employee Range7

Year Founded2022

Last FundingMar 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.